AURKB and lip and oral cavity carcinoma: The primary objective of this study was to comprehensively analyze the effects of co-treating oral cancer cells with small molecules targeting mitotic proteins, specifically an MPS-1 inhibitor (BAY1217389), an Aurora-B inhibitor (Barasertib), and a KSP inhibitor (Ispinesib), in combination with an EGFR inhibitor (Cetuximab).